LymphoStat-BTM A Case Study for Endpoints and Trial Design in SLE

Slides:



Advertisements
Similar presentations
Inhibition of Poly (ADP-Ribose) Polymerase (PARP) by ABT-888 in Patients With Advanced Malignancies: Results of a Phase 0 Trial Shivaani Kummar, MD National.
Advertisements

Developing Immunotherapy for Autoimmune Diseases
Bayan Asem Ibrahim second year pharm.D Instructor : Dr.Adham Abu Taha.
USING BIOMARKERS FOR EARLY PHASE DOSE SELECTION WITH PROTEIN ANTAGONIST DRUGS Ivan Nestorov
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Rituximab (RITUXAN) & Multiple Sclerosis
Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.
Lesokhin AM et al. Proc ASH 2014;Abstract 291.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Use of Monoclonal Antibodies Against Autoimmune Diseases By: Kelly Sambuchi ISAT 351 Spring 1999.
Daclizumab High-Yield Process in Relapsing-Remitting Multiple Sclerosis (SELECT): A Randomised, Double-blind, Placebo-controlled Trial Aaron E. Miller,
An Academic Research Organization of Brigham and Women’s Hospital and Harvard Medical School LAPLACE-TIMI 57 Primary Results A Double-blind, Randomized,
Rapivab™ - peramivir injection
Rituximab for the Treatment of Rheumatoid Arthritis
Safety & Efficacy Update on Approved TNF-Blocking Agents Jeffrey N. Siegel, M.D. OTRR, CBER / FDA Arthritis Advisory Committee March 4, 2003 Jeffrey N.
Abatacept (ORENCIA) for Rheumatoid Arthritis Biological License Application Arthritis Advisory Committee September 6, 2005.
Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.
Comparison of Nilotinib and Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd Beyond One Year Larson.
SCH in Subjects with Relapsed Osteosarcoma or Ewing’s Sarcoma Protocol P04720 CTOS Nov 2008.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Featured Article: Claudia Cavelti-Weder, M.D., Andrea Babians-Brunner, M.D.,
Drug Metabolism and Pharmacokinetics Core Goal: To provide comprehensive pharmacology support for preclinical and clinical research.
Welcome to Workshop #5: Accelerated Approval (AA) in Rare Diseases: Review of a White Paper Proposal Emil D. Kakkis, M.D., Ph.D. President and Founder.
Baran KW August 28, 2000 Kenneth W. Baran MD for the LIMIT AMI Investigators St. Paul Heart Clinic, St. Paul, MN, USA Sponsor: Genentech Inc., South San.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.
D EPARTMENT OF I MMUNOLOGY & H ISTOCOMPATIBILITY – U NIVERSITY OF T HESSALY TNFRSF13B/TACI and TNFRSF13C/BAFFR in B cell chronic lymphocytic leukemia.
Some Design Issues in Microbicide Trials August 20, 2003 Thomas R. Fleming, Ph.D. Professor and Chair of Biostatistics University of Washington FDA Antiviral.
1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Locatelli F et al. Proc ASH 2013;Abstract 4378.
Scientific Basis for Review of Varicella Zoster Immune Globulin Products Blood Products Advisory Committee July 21, 2005 Dorothy Scott, M.D. OBRR/CBER.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Alemtuzumab BLA committee CD52 Expression Leukocytes B- lymphocytes T- lymphocytes Monocytes Macrophages Thymocytes Granulocytes (
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products – Case Studies Anne M. Pilaro, Ph.D. DBOP/OODP/CDER Oncology Drugs.
Carla Chieffo, David Cook, Qinfang Xiang, and Lawrence A. Frohman Efficacy and Safety of an Octreotide Implant in the Treatment of Patients With Acromegaly.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Robert A. Terkeltaub, Daniel E. Furst, Katherine Bennett, Karin A. Kook, R. S. Crockett, and Matthew W. Davis ARTHRITIS & RHEUMATISM Vol. 62, No. 4, April.
Randomized Double Blind Placebo Controlled PK/PD Study On the Effects of a Single Intravenous Dose of the Anti-Hepcidin Spiegelmer ® NOX-H94 On Serum Iron.
01/22/2010 – 7:45pmeSlide – P6617 – MedImmune 4 x 8 Poster Template Detection of a human anti-PDGFR  therapeutic antibody in a human GBM orthotopic rat.
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis R1 신가영 / Modulator Prof. 이연아 N Engl J Med 2015; 373: Philip J.
1 Oliva EN et al Proc ASH 2015;Abstract 91.
Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.
Moskowitz CH et al. Proc ASH 2015;Abstract 182.
A phase I pharmacokinetic and pharmacodynamic study of weekly MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF-1R) monoclonal antibody in patients.
Copyright © 2003 American Medical Association. All rights reserved.
Farletuzumab in platinum sensitive ovarian cancer with low CA125
Monoclonal Antibodies
Senior Medical Director, Cardiovascular
Oxford Niacin Trial.
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
Histamine H1 receptor antagonist
Volume 18, Issue 2, Pages (February 2003)
B-Cell-Directed Therapy for Inflammatory Skin Diseases
ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.
Guidelines for Initiation of Therapy
Association of B cell TLR4 levels to disease activity.
Immunologic and pharmacokinetic studies.
Presentation transcript:

LymphoStat-BTM A Case Study for Endpoints and Trial Design in SLE Presentation to the Arthritis Drugs Advisory Committee 30 September 2003 Bill Freimuth, MD, PhD

Agenda Review BLyS and the pharmacologic rationale, nonclinical and clinical data for LymphoStat-B Review phase 2 trial design in SLE Pose questions related to SLE trial design/endpoints to the Committee for discussion

BLyS B-Lymphocyte Stimulator Identified in a high-throughput proliferation assay A member of the TNF family Alternate names: TALL-1, zTNF4, THANK, BAFF & TNFSF-20 Biologically active, soluble form is a 51 kd homotrimer Binds 3 membrane receptors on B lymphocytes Acts as a survival factor by inhibiting B-cell apoptosis Stimulates differentiation of B cells to Ig-producing plasma cells

Rationale for BLyS Antagonists in SLE Mouse data links BLyS and autoimmune disease Transgenic models over-expressing BLyS have autoimmune/SLE-like phenotype Genetic models of autoimmune disease have elevated levels of circulating BLyS Soluble BLyS receptors administered in an animal model of SLE ameliorates disease progression and improves survival Elevated BLyS levels are evident in the serum of SLE and RA patients BLyS levels positively correlated with serum IgG and autoantibody levels

Autoimmune Patients Display Elevated Serum BLyS Concentrations 5 Normal vs SLE or RA, p <0.001 4 3 BLyS concentration (ng/mL) 2 1 Normal SLE1 SLE2 RA RAsf (From Zhang et al, J Immunol, 2001)

LymphoStat-B Inhibits BLyS Effects in Mice Human BLyS administration stimulates increased spleen weight, B220+/ThB+ splenic B cell numbers and serum IgA LymphoStat-B is a fully human IgG1l monoclonal antibody that specifically recognizes and binds to soluble human BLyS LymphoStat-B selectively inhibits these BLyS-induced effects

LymphoStat-B Inhibits BLyS Induced Serum IgA Increase # 700 # p <0.05 600 # 500 400 Serum IgA (g/mL) # # # # 300 200 100 0.05 0.15 0.5 1.5 5.0 0.05 0.15 0.5 1.5 5.0 Naive IgG1 control (mg/kg) LymphoStat-B (mg/kg) Ab Buffer + BLyS Ab Buffer + BLyS Buffer

LymphoStat-B: Activity and Safety in Cynomolgus Monkeys LymphoStat-B was well tolerated at doses up to 50 mg/kg q2 weeks for 6 months and during an 8-month recovery period No study agent-related infections during treatment or recovery periods Activity of LymphoStat-B is demonstrated by decreases in B lymphocytes Flow cytometry, organ weights and histologic findings correlated with effects on B lymphocytes PK are linear, with a terminal half-life of ~11-14 days Complete results to be presented at ACR

LymphoStat-B Reduces CD20+ Peripheral Blood B-lymphocytes * Statistically significant difference from vehicle control 250 0 mg/kg/dose 225 5 mg/kg/dose 15 mg/kg/dose 200 50 mg/kg/dose 175 150 99% % Baseline CD20+ Cells 125 100 41% 42% 75 * 35% * * * * * 50 * * * * * * 25 Week 13 Week 26 Week 33 Week 39 Week 45 Week 52 Week 60 Treatment Recovery Animals per dose group: 12/16 8/10 4 4 4 4 4

LymphoStat-B: Clinical Development in SLE Phase 1 Clinical Trial 4 IV doses (1, 4, 10 and 20 mg/kg) and placebo evaluated as a single dose or 2 doses 21 days apart Well tolerated No drug-related serious adverse events No increase in adverse events or laboratory abnormalities No increase in incidence of infection Linear pharmacokinetics with ~14 day half-life Biological activity observed Complete results to be presented at ACR Fast Track Designation granted

LymphoStat-B: Phase 2 SLE Trial Design Multi-center, randomized, double-blind, placebo- controlled, dose-ranging (1, 4, 10 mg/kg) Patients with active SLE (SELENA SLEDAI > 4) and on stable medications 350 patients IV administration Day 0, 14, 28 then q28 days for 1 year

LymphoStat-B: Phase 2 SLE Trial Design Primary endpoints SELENA SLEDAI activity at week 24 Time to first flare (defined by SELENA SLEDAI flare index) over 52 weeks Sample Size 80% power,  0.05, to detect in 1 of the active groups a 25% absolute or 100% relative improvement (e.g., 25% to 50%) in the percent change from baseline score in SELENA SLEDAI at Week 24 and a reduction in the percent of subjects having their first flare by Week 52 from 65% to 43%

LymphoStat-B: Phase 2 SLE Trial Design Major secondary endpoints Week 52 SELENA SLEDAI and BILAG scores Time to first flare (defined by BILAG) over 52 weeks Reduction in steroid use AUC of SELENA SLEDAI and BILAG over 52 weeks Biological markers Anti-dsDNA, ANA, and C3 and C4 levels B cells (CD20+, CD27+, CD69+) and plasmacytoid cells (CD138+, CD19/CD27BRIGHT) Total serum IgG and other subclasses

Questions for Committee Discussion Would an effect in either SELENA SLEDAI at 24 weeks or time to first flare over 52 weeks be an adequate basis to move forward to a confirmatory trial? Which endpoint is thought to be more clinically meaningful? Is the magnitude of effect being tested for clinically relevant? Would a lesser effect also be clinically meaningful?

Questions for Committee Discussion Are there other endpoints that would be preferred and considered more clinically meaningful? For example: Would significant benefit in one or more specific SLE organ system manifestations (as defined in BILAG) be a relevant primary endpoint? Would a significant steroid-sparing effect with or without a positive trend in disease activity and/or flare be a sufficient primary endpoint? Which endpoint would be the most compelling as a primary endpoint in a pivotal trial?

Questions for Committee Discussion Several other clinical endpoints and markers of biological activity are being explored Which are believed to be the more meaningful? Is there currently sufficient evidence to consider any of these biomarkers reasonably likely to predict clinical benefit?